Navigation Links
Anadys Pharmaceuticals Reports Fourth Quarter and Year-End 2010 Financial Results and Highlights
Date:3/3/2011

pany's DAA, added to current standard of care for the treatment of hepatitis C.  The Company is also preparing to resume clinical development of ANA773, the Company's oral, small-molecule inducer of endogenous interferons that acts via the Toll like receptor 7, or TLR7, pathway in hepatitis C.

Safe Harbor Statement Statements in this press release that are not strictly historical in nature constitute "forward-looking statements."  Such statements include, but are not limited to, references to (i) the belief that Anadys is well-positioned to create value in the evolving HCV landscape; (ii) Anadys' objective to extend the favorable results seen last year when ANA598 was dosed over 12 weeks with the recently initiated Phase IIb study; (iii) the belief that the ANA598 Phase IIb study should set the stage for Phase III development; (iv) the ability for patients to achieve SVR24 in the ANA598 Phase IIb study; (v) the timing, occurrence and outcome of expected milestone events; and (vi) the plans and expected trial design for advancing ANA773 in development for HCV.  Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause Anadys' actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements.  For example, the results of preclinical and early clinical studies may not be predictive of future results, and Anadys cannot provide any assurances that ANA598 or ANA773 will not have unforeseen safety issues, will have favorable results in ongoing or future clinical trials or will receive regulatory approval.  In addition, Anadys' results may be affected by competition from other biotechnology and pharmaceutical companies, its effectiveness at managing its financial resources, its ability to enter into transactions around its product candidates, its abil
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Anadys Pharmaceuticals Augments Management Team and Board of Directors
2. Anadys Pharmaceuticals to Present at the Lazard Healthcare Conference
3. Anadys Pharmaceuticals to Report Fourth Quarter and Year End 2009 Financial Results
4. Anadys Pharmaceuticals Receives FDA Clearance of Phase II Protocol to Study ANA598 in Combination With Interferon-Alpha and Ribavirin in HCV Patients
5. Anadys Pharmaceuticals Reports Second Quarter 2009 Financial Results and Program Highlights
6. Anadys Pharmaceuticals to Report Second Quarter 2009 Financial Results
7. Anadys Pharmaceuticals, Inc. Announces Strategic Restructuring to Focus Operations on Continuing the Advancement of ANA598
8. Anadys Pharmaceuticals Reports First Quarter 2009 Financial Results and Highlights
9. Anadys Pharmaceuticals to Report First Quarter 2009 Financial Results
10. Anadys Pharmaceuticals to Present at Future Leaders in the Biotech Industry
11. Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... ... ... Costello served as Lead Levee Design Engineering Manager for a feasibility study of ... future storm surge flooding, such as occurred in Hurricane Ike in 2008. , ... protection, Costello also balanced socio-economic and environmental needs and concerns. The team ...
(Date:7/28/2015)... ... ... Strong Animals™ announced today that research conducted by South Dakota State University (SDSU) ... Annual Meeting held July 12-16 in Orlando, FL showed feed additive Stay Strong™ for ... feed containing Stay Strong™ for Dairy Cows took longer than 7.7 hours before there ...
(Date:7/28/2015)... ... July 28, 2015 , ... In terms of value, aluminium ... production volume reached close to 1.84 million tonnes in the same year. As ... of the region’s total aluminium hydroxide production; the country’s aluminium hydroxide production posted ...
(Date:7/28/2015)... 28, 2015 Tauriga Sciences, Inc. (OTCQB:  TAUG) ... company, today announced that its stockholders approved an increase ... of the Company from 1,000,000,000 to 2,500,000,000 at its ... at the Law Offices of Nixon Peabody LLP in ... there were 480,655,929 shares of common stock represented either ...
Breaking Biology Technology:Preventing Storm Surge Flooding in Houston 2Strong Animals™ Announces South Dakota State University Research Demonstrates Stay Strong™ for Dairy Cows Improves Performance and Feed Stability 2EU27 Aluminium Hydroxide Market Analysed and Forecast by BAC Reports in New Research Study Available at MarketPublishers.com 2EU27 Aluminium Hydroxide Market Analysed and Forecast by BAC Reports in New Research Study Available at MarketPublishers.com 3Tauriga Sciences, Inc. Stockholders Approve Increase In Authorized Common Stock 2Tauriga Sciences, Inc. Stockholders Approve Increase In Authorized Common Stock 3
... Ohio and LOD, Israel, November 3 Simbionix,USA ... hands-on,curriculum for training medical professionals, today announced that ... US Marketing Director on,November 10th, 2008. Gary Zamler, ... Simbionix has enjoyed double digit revenue growth in,both ...
... Telomolecular CEO, Matthew Sarad, clarifies the scope and terms of his ... ... (PRWEB) November 3, 2008 -- Telomolecular, a Rancho Cordova, California Corporation, ... therapeutics to treat diseases of aging and cancer, particularly diseases related ...
... compound in sufficient and rapidly produced yields, potentially ... could boost semiconductor capabilities for large-area applications. , ... the first heterometallic gallium-indium hydroxide nanocluster was the ... of nitrosobenzene. , The substitute was identified during ...
Cached Biology Technology:William E. Lewandowski to Lead Simbionix US Marketing Team in Simbionix's Strategic Expansion in the US Market 2Former Telomolecular CEO Clarifies SEC Settlement 2Former Telomolecular CEO Clarifies SEC Settlement 3New nanocluster to boost thin films for semiconductors 2
(Date:7/8/2015)... 2015 Summary Pancreatic cancer is the ... fatal, with a mortality rate of 10.9 deaths per ... cancer patients has highlighted a significant need for new ... met by the current market. A highly active ... varying molecule types and mechanisms of action, which provides ...
(Date:7/7/2015)... -- Research and Markets ( ... "Capacitive Fingerprint Sensors Patent Landscape" report ... fingerprint sensing technology is the most reliable and ... developed. This patent landscape focuses on fingerprint sensors ... of capacitive fingerprint sensors is closely linked to ...
(Date:7/2/2015)... 2015 Research and Markets( ... "Next Generation Biometrics Market by Application, Technology, Function & ... their offering. The next generation biometrics market ... a CAGR of 17.9% between 2015 and 2020 ... the market. Safran SA ( France ...
Breaking Biology News(10 mins):Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3Worldwide Capacitive Fingerprint Sensors Patent Landscape Market Report 2015-2020 - Main IP Holders include Seiko Epson, AuthenTec, Sony and STMicroelectronics 2Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 2Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 3
... HOLE, MATiny, toxic protein particles severely disrupt neurotransmission and ... separate studies by Marine Biological Laboratory (MBL) researchers have ... beta, which has long been known to accumulate and ... "These small particles that haven,t aggregated into plaquesthese ...
... A University of Florida scientist whose interest in ... molecular building blocks that shape appendages ranging from feet ... Early Career Scientist today (Thursday, March 26), a distinction ... Martin Cohn, a developmental biologist and a member ...
... A material developed at the Hebrew University of ... following surgery has led to approval by the U.S. ... use in pediatric cardiac surgery patients. The ... of novel, tailor-made, biodegradable polymers for the prevention of ...
Cached Biology News:Tiny but toxic: MBL researchers discover a mechanism of neurodegeneration in Alzheimer's disease 2UF scientist tapped by Howard Hughes Medical Institute to pursue 'best ideas' 2UF scientist tapped by Howard Hughes Medical Institute to pursue 'best ideas' 3Hebrew University professor's work leads to FDA approval for product 2
Request Info...
Peroxidase Protective Buffer is a diluent formulated to stabilize the activity of Chemicon horseradish peroxidase (HRP)-antibody conjugates at high conjugate dilution for extended periods....
... Species Tissue Array (MSTA) slides were designed to ... tissues from multiple species. Tissue slices from ... slide which can then be treated as a ... in situ hybridization. This format ...
... software is used on Macintosh operating ... of any DNA sequence up to ... placement of primers and GC clamps ... gel electrophoresis (DGGE), constant denaturing gel ...
Biology Products: